Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1998 Oct;79(4):323–327. doi: 10.1136/adc.79.4.323

Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty

W Paterson 1, E McNeill 1, S Reid 1, A Hollman 1, M Donaldson 1
PMCID: PMC1717716  PMID: 9875042

Abstract

OBJECTIVE—To assess the efficacy of a longer acting preparation of the gonadotrophin releasing hormone (GnRH) analogue goserelin (Zoladex LA, 10.8 mg) in 12 girls with central precocious or early puberty.
METHODS—Two girls started treatment de novo; the remainder had been on suppressive treatment for a median duration of 1.5 (range, 0.2-5.6) years. Assessment comprising auxology, pubertal staging, and pelvic ultrasound examination was carried out at weeks 0,4, 8, 10, and 12 (first cycle) and weeks 8, 10, and 12 (second cycle) to evaluate the required injection frequency. Thereafter, assessment was performed on the day of injection. Zoladex LA was given every 12 weeks unless pubertal progression occurred.
RESULTS—Satisfactory control was achieved in eight patients using this regimen, and three patients required more frequent injections. One girl was removed from the study because of clinical progression and extreme mood swings. No serious adverse effects occurred. Mean height velocity during the study period was 4.5 cm/year (range, 3.1-6.6) compared with 6.5 cm/year (range, 3.8-9.6) before treatment in nine patients for whom data were available.
CONCLUSIONS—Zoladex LA was effective in controlling precocious puberty in girls when given at intervals of 9-12 weeks and it is recommended that an initial assessment is made eight weeks after beginning treatment.



Full Text

The Full Text of this article is available as a PDF (114.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brauner R., Adan L., Malandry F., Zantleifer D. Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab. 1994 Aug;79(2):415–420. doi: 10.1210/jcem.79.2.8045957. [DOI] [PubMed] [Google Scholar]
  2. Breyer P., Haider A., Pescovitz O. H. Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty. Clin Obstet Gynecol. 1993 Sep;36(3):764–772. doi: 10.1097/00003081-199309000-00033. [DOI] [PubMed] [Google Scholar]
  3. Crowley W. F., Jr, Comite F., Vale W., Rivier J., Loriaux D. L., Cutler G. B., Jr Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981 Feb;52(2):370–372. doi: 10.1210/jcem-52-2-370. [DOI] [PubMed] [Google Scholar]
  4. Donaldson M. D., Stanhope R., Lee T. J., Price D. A., Brook C. G., Savage D. C. Gonadotrophin responses to GnRH in precocious puberty treated with GnRH analogue. Clin Endocrinol (Oxf) 1984 Nov;21(5):499–503. doi: 10.1111/j.1365-2265.1984.tb01387.x. [DOI] [PubMed] [Google Scholar]
  5. Griffin I. J., Cole T. J., Duncan K. A., Hollman A. S., Donaldson M. D. Pelvic ultrasound findings in different forms of sexual precocity. Acta Paediatr. 1995 May;84(5):544–549. doi: 10.1111/j.1651-2227.1995.tb13691.x. [DOI] [PubMed] [Google Scholar]
  6. Griffin I. J., Cole T. J., Duncan K. A., Hollman A. S., Donaldson M. D. Pelvic ultrasound measurements in normal girls. Acta Paediatr. 1995 May;84(5):536–543. doi: 10.1111/j.1651-2227.1995.tb13689.x. [DOI] [PubMed] [Google Scholar]
  7. Kauli R., Pertzelan A., Ben-Zeev Z., Lewin R. P., Kaufman H., Schally A. M., Schally A. V., Laron Z. Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience. Clin Endocrinol (Oxf) 1984 Apr;20(4):377–387. doi: 10.1111/j.1365-2265.1984.tb03433.x. [DOI] [PubMed] [Google Scholar]
  8. Merke D. P., Cutler G. B., Jr Evaluation and management of precocious puberty. Arch Dis Child. 1996 Oct;75(4):269–271. doi: 10.1136/adc.75.4.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Oostdijk W., Rikken B., Schreuder S., Otten B., Odink R., Rouwé C., Jansen M., Gerver W. J., Waelkens J., Drop S. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child. 1996 Oct;75(4):292–297. doi: 10.1136/adc.75.4.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rangasami J. J., Grant D. B. Familial precocious puberty in girls. J R Soc Med. 1992 Aug;85(8):497–498. doi: 10.1177/014107689208500826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stanhope R., Adams J., Jacobs H. S., Brook C. G. Ovarian ultrasound assessment in normal children, idiopathic precocious puberty, and during low dose pulsatile gonadotrophin releasing hormone treatment of hypogonadotrophic hypogonadism. Arch Dis Child. 1985 Feb;60(2):116–119. doi: 10.1136/adc.60.2.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thomas B. C., Stanhope R., Leiper A. D. Gonadotropin releasing hormone analogue and growth hormone therapy in precocious and premature puberty following cranial irradiation for acute lymphoblastic leukaemia. Horm Res. 1993;39(1-2):25–29. doi: 10.1159/000182690. [DOI] [PubMed] [Google Scholar]
  13. Wheeler M. D., Styne D. M. Drug treatment in precocious puberty. Drugs. 1991 May;41(5):717–728. doi: 10.2165/00003495-199141050-00004. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES